期刊文献+

血源筛查乙型肝炎病毒的新策略

New Strategy of Blood Screening for Hepatitis B Virus
原文传递
导出
摘要 我国是乙型肝炎病毒(HBV)感染高流行地区,由HBV引起的输血相关肝炎的预防和控制日益受到关注,而新的检测技术(如核酸检测)的引入是降低HBV感染风险、提高血源安全的重要措施之一。本文对HBV核酸检测在血源筛查中的应用现状作一综述,并探讨我国HBV血源筛查的策略。 There is a high prevalence of hepatitis B virus (HBV)in China where the prevention and control of transfusiontransmitted hepatitis B has been paid more and more attention. The introduction of novel techniques, such as nucleic acid testing (NAT), is one of the important measures to decrease the risk of HBV infection and increase the blood safety. In this paper, the status of application of NAT for HBV in blood screening is reviewed, and the strategy of blood screening for HBV is investigated.
作者 白玉 常卫红
出处 《中国生物制品学杂志》 CAS CSCD 2010年第8期906-909,共4页 Chinese Journal of Biologicals
关键词 血源筛查 核酸检测 肝炎病毒 乙型 策略 Blood screening Nucleic acid testing(NAT) Hepatitis virus B Strategy
  • 相关文献

参考文献32

  • 1中华医学会肝病学分会,中华医学会感染病学分会.慢性乙肝防治指南[OL].(2005-12-14)[2009-08-10].http://www.chinacdc.netcn/n272442/n272530/n273736/n27378l/n305053/n328570/10465-html.
  • 2中国疾病预防控制中心.全国人群乙肝血清流行病学调查结果[OL]. http://www.chinacdc.net.crdn272442/n272530/n3246177/ 23316.html. 2006-4-23.
  • 3王憬惺.乙型肝炎和输血[J].中国输血杂志,2006,19(z1):16-18. 被引量:14
  • 4Satake M, Taira R, Yugi H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program [ J ]. Transfusion, 2007, 47 ( 7 ): 1197-1205.
  • 5Fang CT. Blood screening for HBV DNA [J]. J Clin Virol, 2006, 36 (Suppl 1): S30-S32.
  • 6Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population[J]. Transfusion, 2002, 42(8): 975-979.
  • 7Stramer SL. Viral diagnostics in the area of blood donor screening. Vox Sang, 2004, 87(Suppl 2): S 180-S183.
  • 8Busch MP. Evolving approaches to estimate risks of transfusiontransmitted viral infections: incidence-window period model after ten years [J]. Dev Biol (Basel), 2007, 127: 87-112.
  • 9Kleinman SH, Busch MR. Assessing the impact of HBV NAT on window period reduction and residual risk [J]. J Clin Virol, 2006, 36 (Suppl 1 ): S23-S29.
  • 10Jackson BR, Busch MP, Strainer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations [J]. Transfusion, 2003, 43 (6): 721-729.

二级参考文献84

共引文献263

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部